INmune Current Deferred Revenue from 2010 to 2026
| INMB Stock | USD 1.32 0.08 5.71% |
Current Deferred Revenue | First Reported 2016-12-31 | Previous Quarter 480 K | Current Value 511 K | Quarterly Volatility 926.5 K |
Check INmune Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among INmune Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 604.2 K, Interest Expense of 1.6 M or Selling General Administrative of 6.8 M, as well as many indicators such as Price To Sales Ratio of 6.1 K, Dividend Yield of 0.0 or PTB Ratio of 2.74. INmune financial statements analysis is a perfect complement when working with INmune Bio Valuation or Volatility modules.
INmune | Current Deferred Revenue | Build AI portfolio with INmune Stock |
Analyzing INmune Bio's Current Deferred Revenue over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Current Deferred Revenue has evolved provides context for assessing INmune Bio's current valuation and future prospects.
Latest INmune Bio's Current Deferred Revenue Growth Pattern
Below is the plot of the Current Deferred Revenue of INmune Bio over the last few years. It is revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. INmune Bio's Current Deferred Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in INmune Bio's overall financial position and show how it may be relating to other accounts over time.
| Current Deferred Revenue | 10 Years Trend |
|
Current Deferred Revenue |
| Timeline |
INmune Current Deferred Revenue Regression Statistics
| Arithmetic Mean | 9,455 | |
| Geometric Mean | 344,493 | |
| Coefficient Of Variation | 4,121 | |
| Mean Deviation | 362,170 | |
| Median | (298,390) | |
| Standard Deviation | 389,595 | |
| Sample Variance | 151.8B | |
| Range | 914.4K | |
| R-Value | 0.85 | |
| Mean Square Error | 46.2B | |
| R-Squared | 0.71 | |
| Significance | 0.000019 | |
| Slope | 65,234 | |
| Total Sum of Squares | 2.4T |
INmune Current Deferred Revenue History
About INmune Bio Financial Statements
INmune Bio stakeholders use historical fundamental indicators, such as INmune Bio's Current Deferred Revenue, to determine how well the company is positioned to perform in the future. Although INmune Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in INmune Bio's assets and liabilities are reflected in the revenues and expenses on INmune Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in INmune Bio. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 562.4 K | 323.7 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether INmune Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of INmune Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inmune Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inmune Bio Stock:Check out the analysis of INmune Bio Correlation against competitors. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. Market participants price INmune higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive INmune Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth 2.571 | Return On Assets | Return On Equity |
INmune Bio's market price often diverges from its book value, the accounting figure shown on INmune's balance sheet. Smart investors calculate INmune Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since INmune Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.